Ernexa Therapeutics Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Ernexa Therapeutics Inc. (ERNA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-13
- Ernexa Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $100.00K, a 98.70% decline from fiscal 2024.
- Ernexa Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $7.70M, a 266.67% increase from fiscal 2023.
- Ernexa Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $2.10M, a 76.14% decline from fiscal 2022.
- Ernexa Therapeutics Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $8.80M, a 30.95% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $100.00K 10-K · filed 2026-03-13 | |
| 2024-12-31 | $7.70M 10-K · filed 2025-03-12 | |
| 2023-12-31 | $2.10M 10-K · filed 2024-03-14 | |
| 2022-12-31 | $8.80M 10-K · filed 2023-03-20 | |
| 2021-12-31 | $6.72M 10-K/A · filed 2022-07-01 | $11.86M 10-K · filed 2022-04-15 |
| 2020-12-31 | $939.00K 10-K · filed 2021-03-11 | |
| 2019-12-31 | $429.00K 10-K · filed 2021-03-11 | |
| 2018-12-31 | $20.00K 10-K · filed 2020-03-19 | |
| 2017-12-31 | $8.90M 10-K · filed 2019-03-22 | |
| 2016-12-31 | $917.00K 10-K · filed 2018-03-09 | |
| 2015-12-31 | $2.41M 10-K · filed 2017-03-09 | |
| 2014-12-31 | $1.73M 10-K · filed 2016-03-15 | |
| 2013-12-31 | -$303.00K 10-K · filed 2015-03-27 | $303.00K 10-K · filed 2014-03-31 |
| 2012-12-31 | $139.00K 10-K · filed 2013-03-29 | |
| 2011-12-31 | $1.11M 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |